WCESP (2 mg/ml) decreases <i>V</i>. <i>cholerae</i> cell-surface hydrophobicity. by Daniel B. Pederson (604306)

Decreased production of IL-12p70 and IL-23 in response to LPS+R848 stimulation in frail old individuals. by Nathalie Compté (418458)

Botulinum toxin A (3.5 U/kg) decreases dural extravasation in IoNC injured rats. by Boris Filipović (336089)

Retnla overexpression decreased the levels of IL-4, IL-5, and IL-13 in OVA-induced asthmatic lung. by Mi-Ran Lee (664596)

Acute intestinal inflammation transiently decreases frequency of colonic LP CD5⁺ B cells. by Yoshiyuki Mishima (842248)

Archazolid decreases the activity and expression of cathepsin B in endothelial cells. by Betty Luong (5738027)

Neutrophils adhered to the apical surface of polarized-MDCK cells augment AdV entry without decreasing the TER. by Poornima L. N. Kotha (701665)

Decreased self-renewal capacity associated with senescence was prevented in human MSCs following treatment with Ki16425, an LPA₁/LPA₃ antagonist. by Masahiko Kanehira (183764)

“…CFU-F colonies initiated from the treated cells (passage 5, 100 cells) were counted after 15 days of normal culture. …”

pGab1 levels decreased over time in HCV-infected Huh7.5.1 cells. by Da-eun Nam (18927946)

<i>In vivo</i> silencing (RNAi) of pairing-dependent lincRNAs decreases the number of <i>S</i>. <i>mansoni</i> adult worms recovered from infected mice. by Gilbert O. Silveira (7376819)

SARS-CoV-2 mutants mediate robust cell-cell fusion. by Prerna Arora (821926)

IFI27 supports LCL survival. by Ken Sagou (1945318)

The mean values of correctly memorized foreground characters and users’ SDNN in different background line orientations. by Yanqun Huang (7487657)

List of Included studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

The search strategy in three databases. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

A summary of the included study characteristics. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

NIH score. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

List of excluded studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

Effect of noradrenaline (NA) alone (A) and NA with α1A- (B), α1B- (C), α1D- (D) and α1A,B,D (E)–adrenoreceptors (ARs) antagonists (a dose of 10⁻⁴ M) on the tension of co... by Barbara Jana (9110179)

Effect of noradrenaline (NA) alone (A) and NA with α1A- (B), α1B- (C), α1D- (D) and α1A,B,D (E)–adrenoreceptors (ARs) antagonists (a dose of 10⁻⁴ M) on the tension of co... by Barbara Jana (9110179)